Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | Buy | TD Cowen | |
| 10/3/2024 | $48.00 | Outperform | Oppenheimer |
| 7/26/2024 | $58.00 | Outperform | Robert W. Baird |
| 6/27/2024 | Overweight | Cantor Fitzgerald | |
| 5/16/2024 | $40.00 | Buy | H.C. Wainwright |
| 2/15/2024 | $44.00 | Buy | Stifel |
| 12/26/2023 | $22.00 | Buy | Jefferies |
| 11/22/2023 | $23.00 | Outperform | Wedbush |
TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy
Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00
Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York CityOppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET, taking place virtually Live webcasts of th
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. A live webcast of the Company's presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDiant
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 Approximately $343 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.